Lung adenocarcinoma as part of the Li-Fraumeni syndrome spectrum : Preliminary data of the LIFSCREEN randomized clinical trial
Ce dossier présente un ensemble d'articles sur les stratégies de surveillance et le dépistage des cancers chez les personnes présentant une prédisposition génétique (syndrome de Lynch ou syndrome de Li-Fraumeni)
Li-Fraumeni syndrome (LFS) is a cancer predisposition caused by germline mutation of the TP53 gene (OMIM 151623). It is characterized by an early age of tumor onset and a broad tumor spectrum including sarcoma, breast cancer, brain tumor, and adrenocortical carcinoma.1 Due to this broad spectrum, surveillance of TP53 mutation carriers is challenging and whole-body magnetic resonance imaging (MRI) represents an attractive strategy.
JAMA Oncology , résumé, 2016